Educational evidence summaries. No dosing, sourcing, or treatment instructions.
The Endocrine Evidence Desk reviews GH, GHRH, IGF-1 and ghrelin-receptor mechanisms using primary research and regulatory sources.
54 published notesAn evidence-led CJC-1295 and Ipamorelin Combination review focused on glucose and metabolic context, human-study limits, regulatory context and claim verification.
Reviewed by Endocrine Evidence DeskAn evidence-led CJC-1295 and Ipamorelin Combination review focused on healthy-aging claims, human-study limits, regulatory context and claim verification.
Reviewed by Endocrine Evidence DeskAn evidence-led CJC-1295 and Ipamorelin Combination review focused on sleep claims, human-study limits, regulatory context and claim verification.
Reviewed by Endocrine Evidence DeskAn evidence-led CJC-1295 and Ipamorelin Combination review focused on animal-to-human translation, human-study limits, regulatory context and claim verification.
Reviewed by Endocrine Evidence DeskAn evidence-led CJC-1295 and Ipamorelin Combination review focused on wada and sport rules, human-study limits, regulatory context and claim verification.
Reviewed by Endocrine Evidence DeskWhy CJC-1295 and Ipamorelin are discussed together, what each receptor pathway does and why mechanism is not proof of clinical benefit.
Reviewed by Endocrine Evidence DeskAn evidence-led CJC-1295 and Ipamorelin Combination review focused on immunogenicity questions, human-study limits, regulatory context and claim verification.
Reviewed by Endocrine Evidence DeskAn evidence-led CJC-1295 and Ipamorelin Combination review focused on receptor pathway map, human-study limits, regulatory context and claim verification.
Reviewed by Endocrine Evidence DeskA structured review of the landmark CJC-1295 healthy-adult trials, including endpoints, results, half-life and what the study cannot establish.
Reviewed by Endocrine Evidence Desk